Table 2.
Use of contact precautions by CF center location (in CF centers ≤200 patients)
| Australia (n = 15) | New Zealand (n = 14) | Not specified(n = 23) | p-value | |
|---|---|---|---|---|
| Contact precautions | ||||
| During hospital admission: | ||||
| All people with CF, n (%) | 8/9 (89%) | 2/5 (40%) | 2/10 (20%) | 0.007 |
| MRSA infection, n (%) | 14/14 (100%) | 9/10 (90%) | 14/15 (93%) | 0.52 |
| MRO infection, n (%) | 11/11 (100%) | 6/7 (86%) | 6/10 (60%) | 0.030 |
| During ambulatory care: | ||||
| All people with CF, n (%) | 5/13 (38%) | 0/13 (0%) | 2/16 (13%) | 0.031 |
| MRSA infection, n (%) | 10/13 (77%) | 3/13 (23%) | 6/16 (38%) | 0.016 |
| MRO infection, n (%) | 10/12 (83%) | 1/10 (10%) | 2/14 (14%) | < 0.001 |
CF cystic fibrosis, MRSA methicillin-resistant Staphylococcus aureus, MRO multi-resistant organism (Burkholderia cepacia complex; Mycobacterium abscessus group)